| 000 | 01848 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517224932.0 | ||
| 264 | 0 | _c20180905 | |
| 008 | 201809s 0 0 eng d | ||
| 022 | _a1613-2246 | ||
| 024 | 7 |
_a10.1007/s10384-018-0605-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOgasawara, Masashi | |
| 245 | 0 | 0 |
_aPrognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. _h[electronic resource] |
| 260 |
_bJapanese journal of ophthalmology _cSep 2018 |
||
| 300 |
_a584-591 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aChoroid _xblood supply |
| 650 | 0 | 4 |
_aChoroid Diseases _xdiagnosis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aFundus Oculi |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 |
_aMacula Lutea _xdiagnostic imaging |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPolyps _xdiagnosis |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xadministration & dosage |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVisual Acuity |
| 650 | 0 | 4 |
_aWet Macular Degeneration _xdiagnosis |
| 700 | 1 | _aKoizumi, Hideki | |
| 700 | 1 | _aYamamoto, Akiko | |
| 700 | 1 | _aItagaki, Kanako | |
| 700 | 1 | _aSaito, Masaaki | |
| 700 | 1 | _aMaruko, Ichiro | |
| 700 | 1 | _aOkada, Annabelle A | |
| 700 | 1 | _aIida, Tomohiro | |
| 700 | 1 | _aSekiryu, Tetsuju | |
| 773 | 0 |
_tJapanese journal of ophthalmology _gvol. 62 _gno. 5 _gp. 584-591 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10384-018-0605-6 _zAvailable from publisher's website |
| 999 |
_c28600548 _d28600548 |
||